Somatic mutations that activate the MAPK pathway in cutaneous melanoma include oncogenic mutations at specific hotspots in NRAS and BRAF (2, 3) and tumor suppressor mutations in negative regulators, such as RASA2 and NF1 (4, 5). This evidence concerns the gene NF1 and neoplasm.